What are the recommended prophylaxis and treatment measures for tumor lysis syndrome in high‑risk patients?

Tumor Lysis Syndrome: Prophylaxis and Treatment in High-Risk Patients

High-risk patients should receive rasburicase plus aggressive hydration in an inpatient setting, while low-risk patients require only allopurinol, hydration, and close monitoring. 1

Risk Stratification

Risk assessment is the critical first step in preventing TLS-related mortality and morbidity. Patients are classified as high-risk if they have at least one of the following factors: 1

Host-Related Factors (Comorbidities):

• Dehydration 1
• Pre-existing renal impairment, including renal infiltration by malignancy 1
• Obstructive uropathy 1
• Hyperuricemia (>8 mg/dL in children, >10 mg/dL in adults) 1
• Hyponatremia (limited to solid tumors) 1

Disease-Related Factors:

• Bulky disease, especially bulky small cell lung cancer or massive liver metastases 1
• Metastatic germ cell tumors (gonadal or extragonadal) 1
• High-grade lymphomas, particularly Burkitt's lymphoma and T-cell lymphoblastic NHL 1
• Acute lymphoblastic leukemia in adults and advanced T-cell ALL in pediatric patients 1
• Elevated serum LDH (>2× upper normal limit) 1

Therapy-Related Factors:

• Intensive polychemotherapy including cisplatin, cytosine arabinoside, etoposide, or methotrexate 1

Pre-Treatment Evaluation

Before initiating prophylaxis, obtain: 1

• Creatinine clearance or estimated GFR 1
• Serum LDH levels 1
• Renal ultrasound in all patients undergoing chemotherapy 1

Patients with previous TLS episodes require nephrology consultation before restarting therapy. 1

Prophylaxis Strategies

High-Risk Patients:

Rasburicase is the cornerstone of prophylaxis in high-risk patients. 1 The evidence strongly supports this approach—a retrospective analysis showed only 2.6% of patients receiving urate oxidase required dialysis compared to 16% receiving allopurinol. 1

• Rasburicase: 0.20 mg/kg/day IV over 30 minutes 1
• Administer first dose at least 4 hours before starting tumor-specific therapy 1
• Continue for 3-5 days 1
• Do NOT give concomitant allopurinol (causes xanthine accumulation and removes substrate for rasburicase) 1
• After completing rasburicase, transition to oral allopurinol 1
• Manage in inpatient setting 1

Critical contraindication: Rasburicase is absolutely contraindicated in patients with G6PD deficiency, methemoglobinemia, or other metabolic disorders causing hemolytic anemia. 1 These patients must receive allopurinol, hydration, and urine alkalinization instead. 1

Low-Risk Patients:

• Allopurinol: 100 mg/m² orally three times daily (maximum 800 mg/day) 1
• Hydration 1
• Urine alkalinization 1
• Close monitoring 1

Intermediate-Risk Patients:

• Hydration plus either allopurinol or rasburicase 1

Hydration Protocol

Hydration is fundamental to both prophylaxis and treatment. 1, 2

• Initiate at least 48 hours before tumor-specific therapy when possible 1
• Target urine output: ≥100 mL/hour in adults (3 mL/kg/hour in children <10 kg) 1
• Monitor hydration status via urine osmolality and fractional excretion of sodium 1
• Loop diuretics may be required to maintain urine output, except in patients with obstructive uropathy or hypovolemia 1
• Check hemodynamic status and hydration level before administering loop diuretics 1

Important caveat: Rasburicase allows earlier chemotherapy initiation if needed, as it rapidly degrades uric acid. 1

Monitoring

High-Risk Patients:

Monitor every 12 hours for first 3 days, then every 24 hours: 1

• LDH, uric acid, sodium, potassium, creatinine, BUN, phosphorus, calcium 1

Established TLS:

Monitor every 6 hours for first 24 hours, then daily: 1

• Vital signs (heart rate, blood pressure, urine output, respiratory rate) 1
• Serum uric acid, electrolytes (phosphate, calcium, potassium) 1
• Renal function (creatinine, BUN, urine pH, osmolality, specific gravity) 1

Monitor every 24 hours: 1

• Blood cell count, serum LDH, albumin, serum osmolality, blood gases, acid-base status, ECG, body weight 1

Treatment of Established TLS

Aggressive hydration and diuresis plus rasburicase or allopurinol for hyperuricemia form the foundation of TLS treatment. 1

Key Management Principles:

• Aggressive IV hydration and diuresis 1
• Rasburicase or allopurinol for hyperuricemia 1
• Alkalinization is NOT recommended 1 This represents a major shift from traditional practice, as alkalinization increases calcium phosphate precipitation and reduces xanthine solubility without improving biochemical abnormalities. 1

Electrolyte Management:

Hyperkalemia: 1

• Calcium gluconate is potentially useful for hyperkalemia-induced cardiac arrhythmias 1
• However, do NOT use calcium gluconate for mild hypocalcemia (increases tissue and renal calcium phosphate precipitation) 1

Renal Replacement Therapy: 3

• Consider early RRT for severe hyperkalemia, hyperphosphatemia, acidosis, or fluid overload unresponsive to diuretics 3
• The threshold for RRT initiation may be lower in TLS than other conditions, as cell breakdown is ongoing and electrolyte increases cannot be predicted 3
• Cytotoxic chemotherapy in high-risk patients should be given in facilities with ready access to dialysis 3

Critical Pitfalls to Avoid

1. Never combine allopurinol with rasburicase during active rasburicase therapy 1
2. Never alkalinize urine in patients receiving rasburicase 1
3. Never use rasburicase in G6PD deficiency 1
4. Never give calcium for mild hypocalcemia (only for life-threatening hyperkalemia with arrhythmias) 1
5. Never delay nephrology consultation in patients with previous TLS episodes 1

The evidence strongly emphasizes that prevention through risk stratification and appropriate prophylaxis is superior to treating established TLS. 1 Recognition of risk factors, vigilant monitoring, and prompt intervention are essential to preventing TLS-related mortality and morbidity. 1